The effectiveness of the JAK1‐selective inhibitor filgotinib in RA‐ILD remains unknown; however, clinical studies have demonstrated the efficacy of JAKis, particularly TOF and BAR, which are both capable of inhibiting JAK1, in treating RA‐ILD. This evidence concerns the gene JAK1 and interstitial lung disease.